

NPLATE (romiplostim)

Effective Date: 1/28/14

Date Developed: 1/28/14 by Robert Sterling, MD

Last Approval Date: 1/26/16, 1/24/17, 1/23/18, 1/22/19

(Archived 1/22/19)

Nplate is an Fc peptide that activates the TPO receptor which leads to the increased production of platelets

Authorization: Nplate is indicated for the treatment of thrombocytopenia in patients with chronic immune thrombocytopenia (ITP) who have had an insufficient response to corticosteroids, immunoglobulins or splenectomy. It is not indicated for any other form of thrombocytopenia.

Dosing: Administer Nplate as a weekly subcutaneous injection with dose adjustments based upon the platelet count response. Initial dose is 1mcg/kg adjusted weekly by 1mcg/kg until platelet count acceptable to reduce the risk of bleeding. Maximum weekly dose is 10mcg/kg

PRECAUTIONS: Rebound thrombocytopenia after discontinuation; bone marrow fibrosis; thrombotic/thromboembolic complications; arthralgias; myalgias; abdominal/extremity pain

DRUG INTERACTIONS: No formal drug interaction studies of Nplate have been performed.

REFERENCES

1. Bussel JB, Buchanan GR, Nugent DJ, et al, "A Randomized, Double-Blind Study of Romiplostim to Determine Its Safety and Efficacy in Children With Immune Thrombocytopenia," *Blood*, 2011, 118(1):28-36.
2. Bussel JB, Kuter DJ, George JN, et al, "AMG 531, a Thrombopoiesis-Stimulating Protein, for Chronic ITP," *N Engl J Med*, 2006, 355(16):1672-81.

3. Bussel JB, Kuter DJ, Pullarkat V, et al, "Safety and Efficacy of Long-Term Treatment With Romiplostim in Thrombocytopenic Patients With Chronic ITP," *Blood*, 2009, 113(10):2161-71.
4. Kuter DJ, "New Thrombopoietic Growth Factors," *Blood*, 2007, 109(11):4607-16.
5. Kuter DJ, Bussel JB, Lyons RM, et al, "Efficacy of Romiplostim in Patients With Chronic Immune Thrombocytopenic Purpura: A Double-Blind Randomised Controlled Trial," *Lancet*, 2008, 371(9610):395-403.
6. Kuter DJ, Mufti GJ, Bain BJ, et al, "Evaluation of Bone Marrow Reticulin Formation in Chronic Immune Thrombocytopenia Patients Treated With Romiplostim," *Blood*, 2009, 114(18):3748-56.
7. Kuter DJ, Rummel M, Boccia R, et al, "Romiplostim or Standard of Care in Patients With Immune Thrombocytopenia," *N Engl J Med*, 2010, 363(20):1889-99. 8Sanz MA, Aledort L, 7.
8. Mathias SD, et al, "Analysis of EQ-5D Scores From Two Phase 3 Clinical Trials of Romiplostim in the Treatment of Immune Thrombocytopenia (ITP)," *Value Health*, 2011, 14(1):90-6.
9. Wang B, Nichol JL, and Sullivan JT, "Pharmacodynamics and Pharmacokinetics of AMG 531, a Novel Thrombopoietin Receptor Ligand," *Clin Pharmacol Ther*, 2004, 76(6):628-38.

Revision History:

Date Reviewed/No Updates: 1/13/15 by C. Sanders, MD
 Date Approved by P&T Committee: 1/27/15
 Date Reviewed/No Updates: 1/26/16 by C. Sanders, MD; R. Sterling, MD
 Date Approved by P&T Committee: 1/26/16
 Date Reviewed/No Updates: 1/24/17 by C. Sanders, MD; R. Sterling, MD
 Date Approved by P&T Committee: 1/24/17
 Date Reviewed/No Updates: 1/23/18 by C. Sanders, MD; R. Sterling, MD
 Date Approved by P&T Committee: 1/23/18
 Date Reviewed/Archived: 1/22/19 by C. Sanders, MD; R. Sterling, MD
 Date Approved by P&T Committee: 1/22/19

Revision Date	Content Revised (Yes/No)	Contributors	Review/Revision Notes
1/24/17	No	Catherine Sanders, MD; Robert Sterling, MD	Annual review
1/23/18	No	Catherine Sanders, MD; Robert Sterling, MD	Annual review
1/22/19	No	Catherine Sanders, MD; Robert Sterling, MD	Archived – check MCG